Immunosuppressant infection risk varies by organ and by drug, and a single regimen cannot be judged across all transplant types. In a registry analysis of solid organ recipients, recorded infection was associated with lower long-term survival, but the same drug linked to fewer infections after liver and heart transplant linked to more after kidney transplant. The lesson is that infection risk belongs to a specific drug, dose, and organ combination, not to immunosuppression in general. The scale of the trade-off is easy to state and hard to manage. Transplant survival has improved sharply, with one-year kidney graft survival moving from roughly 60 to 70 percent to 90 to 95 percent and liver survival from around 20 percent to over 80 percent. That progress depends on suppressing the immune system, and suppression weakens defense against pathogens. Up to 60 percent of recipients develop an infection in the first year, and infection accounts for roughly 12 to 15 percent of deaths after tra...
Antiviral API for CMV infections



